Ute Hennrich, Laurène Wagner, Harun Taş, Luciana Kovacs, Martina Benešová-Schäfer
{"title":"革命性的前列腺癌检测：经批准的PSMA-PET显像剂的作用。","authors":"Ute Hennrich, Laurène Wagner, Harun Taş, Luciana Kovacs, Martina Benešová-Schäfer","doi":"10.3390/ph18060906","DOIUrl":null,"url":null,"abstract":"<p><p>Locametz<sup>®</sup>/Illuccix<sup>®</sup>/Gozellix<sup>TM</sup> (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [<sup>68</sup>Ga]Ga-PSMA-11), Pylarify<sup>®</sup>/Pylclari<sup>®</sup> (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [<sup>18</sup>F]DCFPyL), Radelumin<sup>®</sup> (ABX GmbH (Radeberg, Germany), [<sup>18</sup>F]PSMA-1007), and Posluma<sup>®</sup> (Blue Earth Diagnostics, Ltd. (Oxford, UK), [<sup>18</sup>F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 6","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196200/pdf/","citationCount":"0","resultStr":"{\"title\":\"Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.\",\"authors\":\"Ute Hennrich, Laurène Wagner, Harun Taş, Luciana Kovacs, Martina Benešová-Schäfer\",\"doi\":\"10.3390/ph18060906\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Locametz<sup>®</sup>/Illuccix<sup>®</sup>/Gozellix<sup>TM</sup> (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [<sup>68</sup>Ga]Ga-PSMA-11), Pylarify<sup>®</sup>/Pylclari<sup>®</sup> (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [<sup>18</sup>F]DCFPyL), Radelumin<sup>®</sup> (ABX GmbH (Radeberg, Germany), [<sup>18</sup>F]PSMA-1007), and Posluma<sup>®</sup> (Blue Earth Diagnostics, Ltd. (Oxford, UK), [<sup>18</sup>F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.</p>\",\"PeriodicalId\":20198,\"journal\":{\"name\":\"Pharmaceuticals\",\"volume\":\"18 6\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196200/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/ph18060906\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18060906","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
Locametz®/Illuccix®/GozellixTM (Novartis AG（瑞士巴塞尔）和Telix Pharmaceuticals， Ltd（澳大利亚墨尔本），全部三种[68Ga]Ga-PSMA-11), Pylarify®/Pylclari®（Progenics Pharmaceuticals, Inc.（美国纽约）和Curium PET France SA（法国巴黎），均为[18F]DCFPyL）， Radelumin®（ABX GmbH（德国Radeberg）， [18F]PSMA-1007）和Posluma®（Blue Earth Diagnostics, Ltd.（英国牛津）），[18F]rhPSMA-7.3)是四种已获批准的PSMA-PET显像剂，它们显著促进了前列腺癌的诊断和治疗。这些药物提供了一个新的水平的精度和准确性，使临床医生能够检测前列腺癌与增强的敏感性。因此，它们在改善检测、分期和管理方面发挥着关键作用，最终提高了患者的临床结果。它们在常规临床实践中的应用有望提高诊断精度，并为个性化治疗提供更清晰的途径。这篇综述提供了一个全面的化学、制药和医学综述，讨论了比较研究，并强调了前列腺癌检测的其他高度相关的候选药物。
Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.
Locametz®/Illuccix®/GozellixTM (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [68Ga]Ga-PSMA-11), Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany), [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd. (Oxford, UK), [18F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.
PharmaceuticalsPharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍：
Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
